This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kondagunta, G. V. Articles by Bosl, G. J. Search for Related Content PubMed PubMed Citation Articles by Kondagunta, G. V. Articles by Bosl, G. J.

Etoposide and Cisplatin Chemotherapy for Metastatic Good-Risk Germ Cell Tumors

From the Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine; Department of Urology; and Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center; and Joan and Sanford I. Weill Medical College of Cornell University, New York, NY

Address reprint requests to G. Varuni Kondagunta, MD, Memorial Hospital, 1275 York Avenue, New York, NY 10021; e-mail: kondaguv{at}mskcc.org

PURPOSE: To assess response, overall survival, and relapse-free survival of patients with good-risk metastatic germ cell tumor (GCT) by International Germ Cell Consensus Classification Group (IGCCCG) criteria treated with four cycles of etoposide and cisplatin (EP).

PATIENTS AND METHODS: Two hundred eighty-nine patients with IGCCCG good-risk GCT were treated with four cycles of EP. EP consisted of four cycles of etoposide 100 mg/m² and cisplatin 20 mg/m² on days 1 to 5 every 21 days.

RESULTS: Two hundred eighty-two of 289 patients (98%) achieved a complete response; 269 (93%) responded to chemotherapy alone and 13 (5%) responded to chemotherapy plus surgical resection of viable disease (GCT other than mature teratoma). Seventeen (6%) experienced relapse, and nine (3%) died as a result of disease at a median follow-up of 7.7 years (range, 0.4 to 21.1 years). Sixty-two of 204 patients (30%) with nonseminoma had findings of teratoma or viable GCT at postchemotherapy surgery.

CONCLUSION: Four cycles of EP is a highly effective therapy for patients with good-risk GCT, with a high cure rate, low relapse rate, and little evidence of late relapse. Postchemotherapy surgery resection of residual disease remains an important aspect of treatment for these patients. Four cycles of EP is acceptable as a standard regimen for the treatment of good-risk metastatic GCT, and serves as an alternative to three cycles of bleomycin and etoposide before cisplatin.

Supported by National Institutes of Health Grant No. 5T32-CA-09207-26, a Patrick M. Byrne Grant and the Craig D. Tifford Foundation, Stamford, CT.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

This article has been cited by other articles:

				X. Garcia-del-Muro, P. Maroto, J. Guma, J. Sastre, M. Lopez Brea, J. A. Arranz, N. Lainez, D. S. de Prado, J. Aparicio, J. M. Piulats, et al. Chemotherapy As an Alternative to Radiotherapy in the Treatment of Stage IIA and IIB Testicular Seminoma: A Spanish Germ Cell Cancer Group Study J. Clin. Oncol., November 20, 2008; 26(33): 5416 - 5421. [Abstract] [Full Text] [PDF]

				A. J. Stephenson, G. J. Bosl, R. J. Motzer, D. F. Bajorin, J. P. Stasi, and J. Sheinfeld Nonrandomized Comparison of Primary Chemotherapy and Retroperitoneal Lymph Node Dissection for Clinical Stage IIA and IIB Nonseminomatous Germ Cell Testicular Cancer J. Clin. Oncol., December 10, 2007; 25(35): 5597 - 5602. [Abstract] [Full Text] [PDF]

				R. de Wit Refining the Optimal Chemotherapy Regimen in Good Prognosis Germ Cell Cancer: Interpretation of the Current Body of Knowledge J. Clin. Oncol., October 1, 2007; 25(28): 4346 - 4349. [Full Text] [PDF]

				S Culine, P Kerbrat, A Kramar, C Theodore, C Chevreau, L Geoffrois, N. Bui, J Peny, A Caty, R Delva, et al. Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP) Ann. Onc., May 1, 2007; 18(5): 917 - 924. [Abstract] [Full Text] [PDF]

				R. de Wit and K. Fizazi Controversies in the Management of Clinical Stage I Testis Cancer J. Clin. Oncol., December 10, 2006; 24(35): 5482 - 5492. [Abstract] [Full Text] [PDF]

				G. V. Kondagunta and R. J. Motzer Chemotherapy for Advanced Germ Cell Tumors J. Clin. Oncol., December 10, 2006; 24(35): 5493 - 5502. [Abstract] [Full Text] [PDF]

				J. Oldenburg, J. M. Martin, and S. D. Fossa Late Relapses of Germ Cell Malignancies: Incidence, Management, and Prognosis J. Clin. Oncol., December 10, 2006; 24(35): 5503 - 5511. [Abstract] [Full Text] [PDF]

				L. H. Einhorn and R. S. Foster Bleomycin, Etoposide, and Cisplatin for Three Cycles Compared With Etoposide and Cisplatin for Four Cycles in Good-Risk Germ Cell Tumors: Is There a Preferred Regimen? J. Clin. Oncol., June 1, 2006; 24(16): 2597 - 2598. [Full Text] [PDF]

				G. V. Kondagunta, R. J. Motzer, G. J. Bosl, and J. Sheinfeld IN REPLY J. Clin. Oncol., June 1, 2006; 24(16): 2598 - 2599. [Full Text] [PDF]